

# Trial Evaluating the Tailored Versus the Systematic Use of Defunctioning Stoma After Total Mesorectal Excision for Rectal Cancer (GRECCAR17)

NCT05233787

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Not Applicable
<b>Sponsor</b>	University Hospital, Bordeaux
<b>Enrollment</b>	212 participants

## Plain Language Summary

---

This trial (GRECCAR17) is comparing two surgical approaches for patients with rectal cancer: routinely creating a temporary stoma (a small opening in the abdomen to divert stool) versus only doing so when certain high-risk features are present. The goal is to reduce unnecessary stomas while keeping patients safe.

**\*\*You may be eligible if...\*\***

- You are between 18 and 80 years old
- You have confirmed rectal adenocarcinoma located within 12 cm of the anal opening
- Your cancer has not spread to distant organs (no metastasis)
- You are scheduled for minimally invasive rectal surgery (laparoscopic, robotic, or TaTME) with or without prior chemotherapy or radiation
- You have had a stapled bowel reconnection (anastomosis)

**\*\*You may NOT be eligible if...\*\***

- You have metastatic disease
- You are outside the 18–80 age range
- You have an emergency presentation (obstruction or perforation requiring immediate surgery)
- You have had prior rectal surgery that affects the planned procedure

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (13)

- Age 18-80 years;
- Rectal adenocarcinoma (histologically proven)
- No metastasis or medical history of colorectal metastasis (M0)
- Patients with rectal cancer < 12 cm from the anal verge (determined by rectal examination or MRI)
- Patients operated on by mini-invasive TME (laparoscopic, robotic or TaTME);
- ... and 8 more (see full listing online)

### Exclusion (19)

- Patients with rectal cancer requiring TME surgery with handsewn anastomosis;
- Patients operated on by open approach;
- Previous pelvic irradiation for reasons other than rectal cancer
- Concomitant cancer or medical history of cancer within 5 years other than cancers treated in situ (cervical carcinoma or basocellular carcinoma or spinocellular carcinoma)

<https://clinicaltrials.gov/study/NCT05233787>  
• Patients with expected defunctioning colostomy;

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

... and 14 more (see full listing online)

## Locations (28 total)

---

CHU Amiens-Picardie - Service de Chirurgie Digestive, Amiens, France

CHRU de Besançon - Service de Chirurgie Générale, Digestive et Cancérologique - Unité de Transplantation Hépatique, Besançon, France

CHU de Bordeaux - Service de Chirurgie Digestive et Endocrinienne - Unité Colorectale, Bordeaux, France

... and 25 more locations

---

<https://clinicaltrials.gov/study/NCT05233787>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).